Do analysts rate INKT or FTFT?

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 181.35%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to INKT or FTFT?

In the previous week, MiNK Therapeutics had 5 more articles in the media than Future FinTech Group. MarketBeat recorded 6 mentions for MiNK Therapeutics and 1 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 0.49 beat MiNK Therapeutics' score of 0.45 indicating that Future FinTech Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Future FinTech Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INKT or ANIK?

In the previous week, MiNK Therapeutics had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 6 mentions for MiNK Therapeutics and 2 mentions for Anika Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat Anika Therapeutics' score of -0.06 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anika Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is INKT or IFRX more profitable?

MiNK Therapeutics' return on equity of 0.00% beat InflaRx's return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% InflaRx N/A -53.56% -43.02%

Does the media prefer INKT or IFRX?

In the previous week, InflaRx had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 7 mentions for InflaRx and 6 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat InflaRx's score of 0.29 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InflaRx 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, INKT or GLSI?

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.40 N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.54 N/A

Is INKT or GLSI more profitable?

MiNK Therapeutics' return on equity of 0.00% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -92.37% Greenwich LifeSciences N/A -793.81% -295.32%

Does the media prefer INKT or GLSI?

In the previous week, MiNK Therapeutics had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 6 mentions for MiNK Therapeutics and 1 mentions for Greenwich LifeSciences. MiNK Therapeutics' average media sentiment score of 0.45 beat Greenwich LifeSciences' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Greenwich LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor INKT or BCYC?

In the previous week, MiNK Therapeutics had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for MiNK Therapeutics and 3 mentions for Bicycle Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat Bicycle Therapeutics' score of 0.34 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bicycle Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

MiNK Therapeutics (INKT) Competitors

$12.44 -0.29 (-2.28%)

Closing price 10/2/2026 03:59 PM Eastern

Extended Trading

$12.50 +0.06 (+0.48%)

As of 10/2/2026 07:33 PM Eastern

Compare

INKT vs. FTFT, ANIK, IFRX, GLSI, and BCYC

Should you buy MiNK Therapeutics stock or one of its competitors? MiNK Therapeutics's main competitors and comparable companies include Future FinTech Group (FTFT), Anika Therapeutics (ANIK), InflaRx (IFRX), Greenwich LifeSciences (GLSI), and Bicycle Therapeutics (BCYC). Companies are selected based on similarities in market, industry, and size.

How does MiNK Therapeutics compare to Future FinTech Group?

MiNK Therapeutics (NASDAQ:INKT) and Future FinTech Group (NASDAQ:FTFT) are related small-cap companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

MiNK Therapeutics has a net margin of 0.00% compared to Future FinTech Group's net margin of -157.53%. MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Future FinTech Group	-157.53%	-12.22%	-10.08%

In the previous week, MiNK Therapeutics had 5 more articles in the media than Future FinTech Group. MarketBeat recorded 6 mentions for MiNK Therapeutics and 1 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 0.49 beat MiNK Therapeutics' score of 0.45 indicating that Future FinTech Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Future FinTech Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 181.35%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Future FinTech Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Future FinTech Group has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

Future FinTech Group has higher revenue and earnings than MiNK Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Future FinTech Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Future FinTech Group	$3.83M	8.35	-$4.62M	-$30.16	N/A

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Future FinTech Group shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 1.5% of Future FinTech Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

MiNK Therapeutics beats Future FinTech Group on 9 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Anika Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

Anika Therapeutics has higher revenue and earnings than MiNK Therapeutics. Anika Therapeutics is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Anika Therapeutics	$112.82M	2.27	-$10.88M	-$0.27	N/A

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, Anika Therapeutics has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

MiNK Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 181.35%. Anika Therapeutics has a consensus price target of $22.00, indicating a potential upside of 15.18%. Given MiNK Therapeutics' higher possible upside, research analysts clearly believe MiNK Therapeutics is more favorable than Anika Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anika Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 12.1% of Anika Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

MiNK Therapeutics has a net margin of 0.00% compared to Anika Therapeutics' net margin of -3.14%. Anika Therapeutics' return on equity of 0.20% beat MiNK Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Anika Therapeutics	-3.14%	0.20%	0.15%

In the previous week, MiNK Therapeutics had 4 more articles in the media than Anika Therapeutics. MarketBeat recorded 6 mentions for MiNK Therapeutics and 2 mentions for Anika Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat Anika Therapeutics' score of -0.06 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anika Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Anika Therapeutics beats MiNK Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to InflaRx?

MiNK Therapeutics (NASDAQ:INKT) and InflaRx (NASDAQ:IFRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

MiNK Therapeutics' return on equity of 0.00% beat InflaRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
InflaRx	N/A	-53.56%	-43.02%

MiNK Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, InflaRx has a beta of 2.59, indicating that its share price is 159% more volatile than the broader market.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 181.35%. InflaRx has a consensus target price of $7.43, indicating a potential upside of 331.89%. Given InflaRx's stronger consensus rating and higher possible upside, analysts clearly believe InflaRx is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InflaRx	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

MiNK Therapeutics has higher earnings, but lower revenue than InflaRx. MiNK Therapeutics is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
InflaRx	$30K	8,449.21	-$51.63M	-$0.58	N/A

In the previous week, InflaRx had 1 more articles in the media than MiNK Therapeutics. MarketBeat recorded 7 mentions for InflaRx and 6 mentions for MiNK Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat InflaRx's score of 0.29 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
InflaRx	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InflaRx beats MiNK Therapeutics on 11 of the 15 factors compared between the two stocks.

How does MiNK Therapeutics compare to Greenwich LifeSciences?

MiNK Therapeutics (NASDAQ:INKT) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

In the previous week, MiNK Therapeutics had 5 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 6 mentions for MiNK Therapeutics and 1 mentions for Greenwich LifeSciences. MiNK Therapeutics' average media sentiment score of 0.45 beat Greenwich LifeSciences' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 181.35%. Greenwich LifeSciences has a consensus price target of $69.00, indicating a potential upside of 306.36%. Given Greenwich LifeSciences' higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Greenwich LifeSciences is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A

MiNK Therapeutics' return on equity of 0.00% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Greenwich LifeSciences	N/A	-793.81%	-295.32%

Summary

MiNK Therapeutics beats Greenwich LifeSciences on 6 of the 11 factors compared between the two stocks.

How does MiNK Therapeutics compare to Bicycle Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Bicycle Therapeutics (NASDAQ:BCYC) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

MiNK Therapeutics presently has a consensus target price of $35.00, indicating a potential upside of 181.35%. Bicycle Therapeutics has a consensus target price of $13.86, indicating a potential upside of 309.97%. Given Bicycle Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than MiNK Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

In the previous week, MiNK Therapeutics had 3 more articles in the media than Bicycle Therapeutics. MarketBeat recorded 6 mentions for MiNK Therapeutics and 3 mentions for Bicycle Therapeutics. MiNK Therapeutics' average media sentiment score of 0.45 beat Bicycle Therapeutics' score of 0.34 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bicycle Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics has higher earnings, but lower revenue than Bicycle Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Bicycle Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.40	N/A
Bicycle Therapeutics	$72.86M	3.25	-$218.96M	-$2.73	N/A

MiNK Therapeutics has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -311.11%. MiNK Therapeutics' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-92.37%
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%

2.9% of MiNK Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 20.4% of MiNK Therapeutics shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MiNK Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market. Comparatively, Bicycle Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

Summary

Bicycle Therapeutics beats MiNK Therapeutics on 9 of the 15 factors compared between the two stocks.

Get MiNK Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INKT vs. The Competition

Export

Metric	MiNK Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$63.48M	$3.86B	$7.16B	$13.28B
Dividend Yield	N/A	3.65%	2.54%	17.32%
P/E Ratio	-5.18	13.06	275.66	26.04
Price / Sales	N/A	1,292.11	608.92	91.72
Price / Cash	N/A	123.39	78.87	52.62
Price / Book	-4.11	16.63	10.93	6.31
Net Income	-$12.49M	-$22.71M	$3.51B	$362.16M
7 Day Performance	2.13%	-2.99%	-2.00%	-1.66%
1 Month Performance	6.87%	-10.81%	-6.19%	-4.68%
1 Year Performance	-17.18%	19.19%	8.03%	1.57%

MiNK Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INKT MiNK Therapeutics	2.8075 of 5 stars	$12.44 -2.3%	$35.00 +181.4%	-17.2%	$63.48M	N/A	N/A	15	News Coverage High Trading Volume
FTFT Future FinTech Group	0.333 of 5 stars	$3.41 +1.5%	N/A	-97.6%	$31.50M	$3.83M	N/A	33	Gap Down
ANIK Anika Therapeutics	3.1237 of 5 stars	$19.10 -1.3%	$22.00 +15.2%	+110.6%	$259.09M	$112.82M	N/A	235
IFRX InflaRx	2.1317 of 5 stars	$1.72 +0.6%	$7.43 +331.9%	+8.9%	$252.00M	-$10.10K	N/A	65	News Coverage
GLSI Greenwich LifeSciences	2.1798 of 5 stars	$16.98 -2.1%	$69.00 +306.4%	+55.6%	$249.23M	N/A	N/A	13	News Coverage Negative News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INKT) was last updated on 10/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, ANIK, IFRX, GLSI, and BCYC

How does MiNK Therapeutics compare to Future FinTech Group?

Summary

How does MiNK Therapeutics compare to Anika Therapeutics?

Summary

How does MiNK Therapeutics compare to InflaRx?

Summary

How does MiNK Therapeutics compare to Greenwich LifeSciences?

Summary

How does MiNK Therapeutics compare to Bicycle Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MiNK Therapeutics (INKT) Competitors

INKT vs. FTFT, ANIK, IFRX, GLSI, and BCYC

How does MiNK Therapeutics compare to Future FinTech Group?

Is INKT or FTFT more profitable?

Does the media refer more to INKT or FTFT?

Do analysts rate INKT or FTFT?

Which has more risk and volatility, INKT or FTFT?

Which has higher earnings and valuation, INKT or FTFT?

Do institutionals & insiders have more ownership in INKT or FTFT?

Summary

How does MiNK Therapeutics compare to Anika Therapeutics?

Which has preferable valuation & earnings, INKT or ANIK?

Which has more volatility & risk, INKT or ANIK?

Do analysts prefer INKT or ANIK?

Do institutionals and insiders believe in INKT or ANIK?

Is INKT or ANIK more profitable?

Does the media refer more to INKT or ANIK?

Summary

How does MiNK Therapeutics compare to InflaRx?

Is INKT or IFRX more profitable?

Which has more risk & volatility, INKT or IFRX?

Do insiders and institutionals have more ownership in INKT or IFRX?

Do analysts recommend INKT or IFRX?

Which has better valuation & earnings, INKT or IFRX?

Does the media prefer INKT or IFRX?

Summary

How does MiNK Therapeutics compare to Greenwich LifeSciences?

Do insiders & institutionals believe in INKT or GLSI?

Which has more volatility & risk, INKT or GLSI?

Does the media prefer INKT or GLSI?

Do analysts prefer INKT or GLSI?

Which has higher valuation and earnings, INKT or GLSI?

Is INKT or GLSI more profitable?

Summary

How does MiNK Therapeutics compare to Bicycle Therapeutics?

Do analysts prefer INKT or BCYC?

Does the media favor INKT or BCYC?

Which has higher earnings and valuation, INKT or BCYC?

Is INKT or BCYC more profitable?

Do institutionals & insiders have more ownership in INKT or BCYC?

Which has more volatility and risk, INKT or BCYC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INKT vs. The Competition

MiNK Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools